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Abstract
A phenomenon characterized by the experience of seeing light without any light actually entering the eye is called
phosphenes or photopsias. Phosphenes can occur spontaneously or via induction by external stimuli. Previous reports
regarding phosphenes have primarily focused on externally induced phosphenes such as by applying alternating or direct
current to the cortex. A few of these reports used functional magnetic resonance (fMRI) to study activations induced by
cortical phosphenes. However, there are no fMRI reports on spontaneous phosphenes originating from the retina and the
resulting pattern of cortical activations. We performed fMRI during a reversing checkerboard paradigm in three LCA patients
who underwent unilateral gene therapy and reported experiencing frequent phosphene on a daily basis. We observed
bilateral cortical activation covering the entire visual cortices when patients reported experiencing phosphenes. In contrast,
in the absence of phosphenes, activation was regulated by patient’s visual ability and demonstrated improved cortical
activation due to gene therapy. These fMRI results illustrate the potential impact of phosphene perception on visual
function and they may explain some of the variability that clinicians find in visual function testing in retinal degeneration.
Although we did not perform correlations between visual function and phosphenes, we hope data presented here raises
awareness of this phenomenon and its potential effect on visual function and the implications for clinical testing. We
recommend a thorough history for phosphene experiences be taken in patients with retinal disease who are candidates for
gene or molecular therapy. Lastly, these data illustrate the potential power of fMRI as an outcome measure of gene therapy
and the negative impact phosphenes may have on vision testing. fMRI has proven to be a sensitive, non-invasive, and
reproducible test paradigm for these purposes and can complement standard visual function testing.
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Introduction
A phenomenon characterized by the experience of seeing light
without any light actually entering the retina is called a phosphene.
This phenomenon is also known as photopsias and the two terms
have been used interchangeably in the literature. The most
familiar type of phosphene is the pressure phosphene, which is
elicited by pressing on the orbit, e.g. rubbing of the eyes.
According to a pupil of Aristotle, it was Alcmaeon of Croton (circa
530–470 BC) who first reported that ‘‘the eye obviously has fire
within, for when it is stuck this fire flashes out,’’ [1]. Phosphenes
can occur not only through external stimuli, but also through
drugs [2,3], ionizing radiation [4–7], electrical [8–13], or magnetic
stimulation [14–19] of the visual cortex, such as via Transcranial
Magnetic Stimulation (TMS) [14–19]. Meister et al. [20]
performed single-pulse TMS on 22 healthy subjects and observed
that, with the same intensity TMS, some subjects experienced
phosphenes and some didn’t. The authors followed up their
experiments with fMRI using checkerboard stimuli to investigate
neurological differences between phosphene perceivers and non-
perceivers. Subjects who did not report phosphenes had slightly
greater activation in the primary visual cortex (V1). Subjects who
did report phosphenes had greater extra striatal activation such as
in V2/V3 areas. The authors concluded that the level of extra
striatal activation seemed to be related to phosphene perception
whereas the level of striate activation did not play a critical role,
suggesting that phosphene perception may be related to the
processing of information in V2 and V3 areas rather than V1. A
more recent study [21] used simultaneous TMS and fMRI on 12
healthy subjects to record cortical activation induced by TMS.
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[21]. While all subjects demonstrated widespread cortical
activations in response to TMS, subjects who reported seeing
phosphenes had more significant and greater areas of activation
within their visual cortex including the primary visual cortex [21].
A recent study using simultaneous TMS and electroencephalog-
raphy (EEG) also concluded that phosphene perception arises
after extensive processing in the brain. [22].
In addition to using magnetic stimulation, which induces
electrical currents in the brain via changing magnetic fields,
direct electrical stimulation of the occipital lobe also elicits
phosphenes. Non-invasive electrical stimulation of the occipital
lobe, such as transcranial Direct Current Stimulation (tDCS) of
the V1 area has also been shown to elicit phosphenes [11,12].
Furthermore, the non-invasive electrical stimulation technique,
transcranial alternating current stimulation (tACS), over the
occipital lobe has been shown to induce phosphenes as well [23].
In fact, using tACS has brought up the issue of whether the
phosphenes are solely originating from the occipital area or
whether there may be a component with retinal origin as well
[13]. Schutter and colleagues [13] performed frontal and
occipital tACS on 8 healthy volunteers and reported that tACS
of the frontal lobe not only evoked phosphenes but that the
phosphenes evoked by the frontal stimulation, reported by the
same subjects, were significantly more intense than those evoked
by occipital stimulation. Schutter et al [13] hypothesized that in
the case of frontal lobe stimulation much of the current may have
leaked through the scalp into the retina, and the reported
phosphenes may have been caused by stimulation of the retina.
Beyond externally induced phosphenes, phosphenes may also
occur spontaneously in individuals with diseased retinas, in
normal subjects exposed to high-energy radiation [4–7] or taking
certain medications [2,3], or during intraocular insults, such as
posterior vitreous detachment [24,25] or in individuals with a
range of retinal or CNS diseases, including retinal detachment or
inflammatory, ischemic, autoimmune or degenerative disease
[26,27]. An example of fMRI from spontaneously generated
phosphenes also presented in a case study of an individual with
brain infarct [28]. In retinal degenerative diseases, phosphenes
may be the manifestations of spontaneous activity in degenerating
retinal cells due to remodeling of the inner retina or to an
unregulated overproduction of free radicals that produce bio/
chemiluminescent photons [29]. Chemiluminescent photons are
then absorbed by the photoreceptors and initiate a photo-
transduction cascade, which results in the perception of
phosphenes [30]. Narici et al. [31] later revealed that the lipid
peroxidation of the photoreceptors can produce (bio)chemilumi-
nescent photons that generate anomalous visual effects, such as
those associated with retinal phosphenes [31]. One of the most
severe group of retinal degenerative diseases is Leber’s Congen-
ital Amaurosis (LCA), a disease characterized by profound
impairment of the retina and poor visual function in infancy and
early childhood followed by progressive degeneration and loss of
retinal cells [32–34]. In our studies developing fMRI as an
outcome measure for gene therapy intervention in LCA2, we
were struck by the fact that many of the patients reported
experiencing phosphenes, and a few on a daily basis, which was
not revealed in their clinical history. Furthermore, there are no
studies investigating fMRI results of patients with retinal
degenerative disease reporting phosphenes. In this report we
describe, for the first time, fMRI results from several LCA2
patients during episodes of phosphenes and in the absence of any
phosphenes. We show that patients who spontaneously see
phosphenes have immense and significant activation in their
occipital lobes covering all retinotopic visual centers in the brain
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whereas they show minimal activation (depending on their age and
stage of LCA) when they do not experience phosphenes. The
results of this study demonstrate the impact that phosphenes have
on vision and on fMRI testing in patients with LCA2 and suggest
that queries into phosphene experience could be helpful for
understanding test-to-test variations in vision testing.
Materials and Methods
A. Study Participants
Patients were selected from an ongoing neuroimaging study of
LCA2 patients who had received unilateral subretinal injection of
AAV2.hRPE65v2 [32,33,35] in a separate clinical study (www.
clinicaltrials.gov NCT00516477; [32,35]). fMRI results were
previously reported for the first three patients who underwent
fMRI after unilateral gene therapy (subjects CH08, CH09, and
CH13) [34]. The present study aimed to characterize the effects of
phosphenes on the fMRI-measured cortical response to reversing
checkerboard stimuli, in three LCA2 patients (NP02, CH08, and
CH11), from the eye treated with gene therapy (the right eye) and
the left (untreated) eye. For comparison purposes we also present
the fMRI results of two normally sighted controls that report not
experiencing phosphenes (Table 1).
B. Ethics Statement
The institutional review board (IRB) at the Children’s Hospital
of Philadelphia (CHOP) under the IRB protocol number 09-
007165 approved this study. After a complete description of the
fMRI study was provided, written informed consent (and when
necessary, parental permission consent and child assent) was
obtained from all subjects. The CHOP Institutional Review Board
(IRB) approved all study procedures. All patients had been
clinically assessed as part of their qualification to enter the clinical
trial for retinal gene therapy [32,33,35].
Figure 1. Real time patient monitoring. Real time fMRI software allows continuous monitoring of subject’s cortical response for specific regions
of interest (ROIs) placed in the area of interest. In the example above, two ROIs (white and green circles shown with white arrows) are selected in the
right and left primary visual cortex (V1) located in the medial aspect of the occipital lobes encompassing the calcarine fissures. Real time fMRI
monitoring also allows motion detection in three translational and three rotational orientations depicted in the B and C panels respectively.
Experiments are interrupted if no response is detected in panel A or the rotational and translational movements are.0.6.
doi:10.1371/journal.pone.0086068.g001
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C. Magnetic Resonance Imaging
C1. Image Acquisition. MRI scans were conducted at The
Children’s Hospital of Philadelphia (CHOP) on a 3T Siemens
Verio system dedicated to research using a 32 channel head coil.
All scans were carried out by a single operator and monitored to
be free of artifacts at the time of acquisition.
C1.1. Functional MR (fMRI). Functional data were acquired
using the blood oxygenation level dependent (BOLD) technique
acquiring 90 functional volumes of 46 slices with 3 mm isotropic
resolution (Matrix = 64664; TR/TE 3000/30 ms) with a total
acquisition time of 4:39 minutes. To permit T1 saturation, three
additional volumes were acquired at the beginning of the fMRI
experiment, which were not used in image analysis. A transistor-
transistor logic (TTL) pulse was used to automatically start the
stimuli in-synch with the start of fMRI acquisition. An MRI
compatible response device (a button that the subject pushed when
recognizing the stimulus) was used to record subject responses.
Subjects were instructed to press the button once when the
checkerboard first appeared and, if they experienced phosphenes,
to press and hold the button for the duration of the phosphene. If
the subjects reported seeing phosphenes, additional acquisitions
were performed until a phosphene free session was acquired.
However, in the present study we analyzed the acquisitions in
which subjects reported phosphenes and compared them to
acquisitions in which no phosphenes were reported for that
subject.
C1.2. Real Time Patient Monitoring. Real time monitoring
of patient motion and task performance was performed using the
real time fMRI feature available on the Verio research MR system
(Figure 1). As shown in the coronal and sagittal views located at
the top section of Figure 1, two regions of interest (ROI) within the
right and left primary visual cortex (V1) are selected (green and
white circles depicted by white arrows) that are located in the
medial aspect of the occipital lobes encompassing the calcarine
fissures to monitor patients performance. The bottom panel shows
how the patient is being monitored in real time. Experiments are
interrupted if no response is detected in panel A and/or the
rotational and translational movements depicted in panels B and
C are .0.6. This feature allows reliable acquisition of fMRI from
each participant and confirms that the subject is alert and awake
and performing the task. In cases where the subject may have
fallen asleep or may not have been paying attention to the task, the
green and red lines would disappear in panel A.
C1.3. 3D T1 Weighted (MPRAGE). A 3D isotropic structural
high resolution T1 sequence with inversion preparation pulse was
obtained for visual activation localization and generation of
inflated and flat hemispheres (IR-Prep: TR= 2080 ms,
TE= 2.54 ms, BW=180 Hz/Px, matrix size = 3206320,
FOV=2566256 mm2, 192 axial slices, slice thickness = 0.8 mm,
inversion time= 1200 ms with Flip Angle = 8u, NEX=1, Echo
Spacing = 7.8 iPAT=2 and scan time= 7:04 minutes).
C2. fMRI Visual Paradigm. Checkerboard patterns with a
constant (low) light intensity of 5 lux were used in a block design
fMRI paradigm with 3 levels of contrast: high, 100%; medium,
34%; low, 10% [34]. As shown in Figure 2 the checkerboard
paradigm consisted of 15-second active blocks of contrast-
reversing (8-Hz) black and white checkerboards interleaved with
15 seconds of blank (black) screens as control blocks. Subjects were
asked to fixate on the yellow cross in the center of the pattern, or, if
they could not see the cross, were asked to look straight ahead.
Stimuli were presented to one eye at a time and the switch
between eyes took place electronically, thus each subject complet-
ed the task for each eye separately. Resonance Technology
VisuaStim (Northridge, CA) goggles featuring a digital display of
500,000 pixels per 0.25 square inch, and a 30u horizontal field of
view were used to present the fMRI stimuli unilaterally to each
eye. The visual paradigm was programmed in E-Prime (Psychol-
ogy Software Tools, Inc., Pittsburgh, PA).
C3. fMRI Image Preprocessing. All functional data from
individual subjects were processed using BrainVoyager-QX (Brain
Innovations, Maastricht, The Netherlands) [36]. Pre-processing of
data included slice scan time correction, 3D motion correction,
spatial smoothing, and temporal filtering. Since interpolation was
used for scan time correction to insure that all voxels in the volume
represented the signal simultaneously. A high-pass temporal filter
of 2 cycles/run was applied to remove signal drift. Spatial
smoothing was performed using a 3 mm full-width at half-
maximum (FWHM) Gaussian filter. In addition to real time
monitoring of subject motions, to rule out excessive motion, all
functional data sets were additionally processed using the motion
correction algorithm implemented in BrainVoyagerQX that
calculates head translation (in millimeters) and rotation (in degree)
for each volume in relation to the first volume. None of the
subjects showed excessive motion during the scan ($0.6 mm).
Data was analyzed in BrainVoyagerQX using the general linear
model (GLM). Each condition (high, medium, low contrast) was
analyzed by specifying a design matrix defined as blocks with
checkerboard presentation (active) versus blocks with blank black
screen (rest) conditions followed by application of the hemody-
namic response function and corrected for multiple comparisons
using the false discovery rate (fdr). Although subjects reported
seeing phosphene randomly during one of the high, low, or
medium contrasts, for clarity fMRI results presented here are all
from when subjects experienced phosphenes during the high
contrast stimuli (high contrast – rest). However, it is important to
mention that the intensity of cortical activations for the
phosphenes occurring during the medium and low contrast stimuli
were highly comparable to those reported here for the high
contrast condition. fMRI results for the LCA patients are
presented for the left and the right eyes with and without
phosphenes to demonstrate the magnitude and distribution of
cortical activations in the presence of phosphene in comparison to
its absence. fMRI results for the presence of phosphene in all three
LCA patients are presented at the most strict statistical threshold
of fdr,3% along with a continuous connected area of
.1000 mm2. In contrast, fMRI data in the absence of phosphene
are presented at a much more relaxed statistical threshold.
Figure 2. fMRI stimuli and paradigm design. (A) Checkerboard
stimuli with a constant light intensity of 5 lux at three levels of contrast:
high (H; 100%), medium (M; 34%) and low (L; 10%), were presented in a
boxcar block design. (B) The checkerboard paradigm consisted of 15 sec
active blocks of contrast reversing (8 Hz) checkerboards interleaved
with 15 sec presentations of a blank (black) screen as control blocks
(rest period). Three blocks of each contrast were interspersed randomly
and interleaved with nine rest blocks.
doi:10.1371/journal.pone.0086068.g002
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Table 2. Cluster information of activated brain regions for LCA2 patients while not experiencing phosphenes.
Subject ID/Eye Cluster Location (Centroid)
Cluster Size
(mm2) Centroid X Centroid Y Centroid Z t-Value p-Value
CH08/Left Left lingual gyrus, BA 18 628 210 286 24 3.9670 0.0002
Left middle occipital gyrus, BA 18 548 230 294 3 4.2950 0.0000
Right middle occipital gyrus, BA 18 625 27 283 28 4.0176 0.0001
Right cuneus, BA 17 322 17 283 9 3.5775 0.0006
Right middle occipital gyrus, BA 18 407 27 283 28 3.9160 0.0002
Right lingual gyrus BA 17 977 9 296 29 4.0441 0.0001
CH08/Right Left middle occipital gyrus, BA 18 2041 222 289 5 6.1174 0.0000
Left lingual gyrus, BA 18 2637 224 274 27 7.3997 0.0000
Left middle occipital gyrus, BA 19 2388 235 277 6 7.5364 0.0000
Right fusiform gyrus, BA 19 2801 37 274 212 8.5140 0.0000
Right cuneus, BA 18 5123 12 285 21 7.2910 0.0000
Right lingual gyrus, BA 18 4931 13 276 6 7.5045 0.0000
CH11/Left Left lingual gyrus, BA 18 350 27 292 212 12.1390 0.0000
Left cuneus, BA 17 222 27 2101 22 17.1579 0.0000
Left lingual gyrus, BA 18 414 210 259 3 11.5825 0.0000
CH11/Right Left lingual gyrus, BA 17 558 27 290 26 3.7612 0.0003
Left middle occipital gyrus, BA 18 1636 219 285 28 7.1139 0.0000
Left inferior occipital gyrus, BA 18 2426 232 292 29 11.6948 0.0000
Left inferior occipital gyrus BA 18 5432 240 283 23 8.4111 0.0000
Right lingual gyrus, BA 18 3908 17 275 29 6.0228 0.0000
Right lingual gyrus, BA 17 242 10 295 0 3.3365 0.0013
Right lingual gyrus, BA 18 1025 5 286 21 6.0472 0.0000
Right cuneus, BA 17 223 11 274 11 3.1100 0.0025
NP02/Left Left middle occipital gyrus, BA 19 6937 231 288 10 5.7497 0.0000
Left fusiform gyrus, BA 19 1302 231 265 27 5.3607 0.0000
Left middle occipital gyrus, BA 19 1681 226 294 18 6.2505 0.0000
Right lingual gyrus, BA 17 11962 21 290 2 6.2937 0.0000
NP02/Right Left middle occipital gyrus, BA 18 1483 231 290 3 4.2953 0.0000
Right middle occipital gyrus, BA 18 2557 28 292 2 4.1568 0.0001
doi:10.1371/journal.pone.0086068.t002
Table 3. Cluster information of activated brain regions in LCA2 patients when experiencing phosphenes.
Subject ID/Eye Cluster Location (Centroid)
Cluster Size
(mm2) Centroid X Centroid Y Centroid Z t-Value p-Value
CH08/Left Left inferior occipital gyrus, BA 18 34431 235 296 215 13.2272 0.0000
Right cuneus, BA 17 29409 16 280 14 9.7000 0.0000
CH08/Right Left cuneus BA 17 46849 217 296 2 19.6190 0.0000
Right lingual gyrus, BA 18 40249 15 283 23 15.0627 0.0000
CH11/Left Left middle occipital gyrus, BA 18 22469 228 287 23 13.3473 0.0000
Right middle occipital gyrus, BA 18 24523 29 283 3 15.2940 0.0000
CH11/Right Left lingual gyrus, BA 18 25039 26 277 23 13.8245 0.0000
Right cuneus, BA 17 31109 5 271 12 12.5168 0.0000
NP02/Left Left lingual gyrus, BA 18 44082 222 274 21 16.4914 0.0000
Right middle occipital gyrus, BA 19 46505 32 285 11 23.1436 0.0000
NP02/Right Left middle occipital gyrus, BA 19 44352 234 279 3 12.3921 0.0000
Right middle occipital gyrus, BA 19 44440 32 285 11 12.3134 0.0000
doi:10.1371/journal.pone.0086068.t003
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Results
A. Demographics and Overall Phosphene Experiences
Demographic information, RPE mutation type, dose/volume of
AAV2-hRPE65v2, and time between fMRI and gene therapy are
presented in Table 1 [35]. Three of the ten clinical trial
participants (CH08, NP02, and CH11; Table 1) reported that
they had experienced phosphenes their entire lives, often several
times in one day. These were characterized variously as moving
horizontal and/or vertical lines, circles or semi-circular shapes,
crescent moons, lightning bolts, swirling waves, and flashes
covering the entire visual field. In addition to their transient
photopsias, some patients reported experiencing constant back-
ground noise with sparklers or statics. The patients indicated that
when it occurs they have to wait for it to be over before they can
continue with their activities. There was no clear correlation of
phosphene experience with other disease variables. For example,
NP01 and NP02 are fraternal twins and are homozygous for the
RPE65 E102K mutation (Table 1), but only NP02 experiences
phosphenes. Phosphenes can be experienced by young individuals
(CH08, age 12) or by individuals in their late twenties, or early
thirties (CH11, NP02; Table 1). As depicted in Table 1, all three
LCA patients presented with varying measures for visual acuity
and no correlation was observed between phosphenes and visual
acuity.
B. fMRI Results and Phosphene History of LCA2 Patients
Specific characteristics for significant clusters of brain activa-
tions such as cluster size, Talairach coordinates for the centroid
cluster location, cluster statistics, and neurological identification of
the activated regions along with designated Brodmann areas (BA)
are presented in Tables 2 and 3 for LCA2 patients during non-
phosphene and phosphene experiences, respectively.
The detailed information on phosphene experiences and fMRI
results for LCA2 patients are as follows:
NP02, a 31 year old Caucasian male, reported seeing
spontaneous flashes in his left eye almost every day, several times
Figure 3. fMRI results for NP02 left and right eye (treated eye) with and without experiencing phosphenes. (A) fMRI results from the left
eye when presented with the same checkerboard stimuli, when no phosphene was reported, showed significant clusters of activations (fdr,5%,
Corrected p,0.004, cca$100 mm2) which were primarily distributed on the lateral aspects of visual cortex with minimal spread to the medial surface
of the right hemisphere. (C) fMRI results from the right eye (treated eye) when presented with the same checkerboard stimuli while no phosphene
reported by the subject (Uncorrected p,. 010, cca.100 mm2). (D) Similar to the left eye, visual cortex showed extraordinary amount of activations in
response to the checkerboard stimuli presented to the right eye (treated eye) in the presence of phosphenes. fMRI results showed significant
widespread (fdr,3%, Corrected p,0.006, cca $1000 mm2) bilateral activations extending and spreading to all visual centers of occipital cortex. (B)
fMRI results for the left eye when presented with checkerboard stimuli showed significant widespread (fdr,3%, Corrected p,0.005, cca
$1000 mm2) activations that were bilaterally distributed to all areas of visual cortex, when NP02 reported experiencing phosphene.
doi:10.1371/journal.pone.0086068.g003
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a day, but reported not experiencing phosphenes in his right eye as
often. Notably, NP02 had received subretinal gene therapy four
years prior to his MRI scan [32] (Table 1). He reported that the
flashes of light were always composed of bright white glows (not
colored) that generally lasted a few seconds. NP02 described his
phosphenes as having the shape of a half moon (crescent shape)
that move around and at times rotate in his field of vision and
sometimes appear in the shape of vertical lines that move
horizontally in his visual field. NP02 also reported seeing dimmer
twinkling star-like flashes but less often. He also added that he sees
phosphenes both when his eyes are open and closed, but he mostly
experiences them in dark environments. He added that his
phosphenes never occur in bright daylight. NP02 also reported
that he is unable to see his surroundings while experiencing
phosphenes.
fMRI results from the left (untreated) and right (treated) eye of
NP02 are presented in Figure 3. As depicted in panel A, in the
absence of phosphenes, NP02 presented with significant activation
for his untreated eye (left) (cca.100 mm2, Corr. p,0.004,
fdr,5%) as compared to his treated eye (cca.100 mm2, Uncorr.
p,0.010), shown in panel C. Notably, his treated retina had a
macular hole [32,33]. In the presence of phosphene, NP02 had
sizeable significant (fdr,3%, Corr. p,0.006, cca $1000 mm2)
and widespread bilateral cortical activations in response to the
same checkerboard stimuli presented to his right (gene therapy-
treated) eye (Panel D). Similar to his right eye, in the presence of
phosphene, NP02 also showed similar significant widespread
(fdr,3%, Corr. p,0.005, cca $1000 mm2) activations that also
were bilaterally distributed to all areas of visual cortex when he
was presented with the same checkerboard stimuli to his left eye
(Panel B). In summary, there was not a clear improvement in
Figure 4. fMRI results for CH08 left and right eye (treated eye) with and without experiencing phosphenes. (A) fMRI results from the left
eye when presented with the same checkerboard stimuli and no phosphene was reported showed small areas of activations detectable only at a less
stringent statistical threshold (not fdr corrected) and much lower extent threshold (Uncorrected p,0.005, cca $50 mm2). (C) fMRI results from the
right eye (treated eye) when presented with the same checkerboard stimuli and no phosphene reported by the subject. CH08 presented with
significant activations for his treated eye (fdr,5%, Corrected p,0.005 cca.100 mm2) as compared to his untreated eye (left). However, although
there are noticeably more activations for the treated eye, the magnitude and distribution of cortical activations for the treated eye when
experiencing phosphene are significantly greater (D). (B) fMRI results showed significant widespread (fdr,3%, Corrected p,0.004, continuous
connected area (cca) $1000 mm2) bilateral activations in all areas of visual cortex extending from medial to lateral and posterior to anterior aspects
of the occipital cortex after presentation of checkerboard stimuli to his left eye while experiencing phosphene. (D) Similar to the left eye, visual cortex
showed remarkable response to the checkerboard stimuli presented to the right eye (treated eye) while under the influence of phosphenes. fMRI
results showed significant widespread (fdr,3%, Corrected p,0.004, cca$1000 mm2) bilateral activations extending and spreading to all brain visual
centers.
doi:10.1371/journal.pone.0086068.g004
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cortical function in the gene therapy-treated eye, however
phosphene perception in the untreated eye still resulted in strong
activation of widespread cortical areas.
CH08, a 13 year old Caucasian male, reported spontaneous
black and white flashes in both eyes. He also reported seeing
moving horizontal or vertical lines and sometimes wave patterns of
varying intensities. He reported seeing phosphenes both when his
eyes are open and closed, but said he sees them more frequently in
dark environments. CH08 reported that the frequency of his
phosphenes has decreased somewhat since gene therapy (3 years
prior to the fMRI) but still occurs often. CH08 also stated that the
phosphenes last for a few seconds and he is not able to see when
they occur.
fMRI results for CH08’s left (control) and right (treated) eyes
with and without experiencing phosphenes are presented in
Figure 4. In the absence of phosphenes (Panel A, Figure 4) CH08
showed small areas of activations detectable only at a less stringent
statistical threshold (not fdr corrected) and much lower extent
threshold (uncorrected p,0.005, cca $50 mm2). In contrast,
fMRI results from CH08’s right (treated) retina in the absence of
phosphenes (panel C) showed significant activation (fdr,5%,
corrected p,0.005, cca.100 mm2), as compared to his untreated
(left) eye.
When phosphenes were present (panel B), and stimuli were
presented to the control eye, fMRI results showed significant
widespread (fdr,3%, corrected p,0.004, continuous connected
area (cca) $1000 mm2) bilateral activations in all areas of the
visual cortex extending from medial to lateral and posterior to
anterior aspects of the occipital cortex. A similar result was found
when the right (treated) eye was stimulated with light while the
subject perceiving phosphenes (panel D). There was significant
widespread (fdr,3%, corrected p,0.004, cca $1000 mm2) of
bilateral activations extending and spreading to all visual centers
for the treated eye.
CH11, a 28 year old female, reported seeing two types of
spontaneous black and white flashes in both her eyes. The first
Figure 5. fMRI results for CH11 left and right (treated) eye with and without experiencing phosphenes. (A) fMRI results from the CH11
left eye, when presented with the same checkerboard stimuli and phosphenes were absent, showed limited areas of activations detectable only at a
less stringent statistical threshold (Uncorrected p,0.010, cca $100 mm2). (C) fMRI results from the right eye (treated eye) when presented with the
same checkerboard stimuli and no phosphene was reported. CH11 presented with significant activations for her treated eye (Uncorrected p,0.01,
cca.100 mm2) as compared to her untreated eye (left). However, although there is noticeably more activation for CH11’s treated eye, the magnitude
and distribution of cortical activations for the treated eye when experiencing phosphene (D) are significantly more. (B) fMRI results showed significant
widespread (fdr,3%, Corrected p,0.003, cca $1000 mm2) bilateral activations in all areas of visual cortex extending from medial to lateral and
posterior to anterior aspects of the occipital cortex after presentation of checkerboard stimuli to the left eye while experiencing phosphene. (D)
Similar to the left eye, visual cortex showed significant widespread responses (fdr,3%, Corrected p,0.004, cca $1000 mm2) to the checkerboard
stimuli presented to the right eye (treated eye) while CH11 reported seeing phosphenes.
doi:10.1371/journal.pone.0086068.g005
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kind occurs almost all the time and is described as a black and
white background noise similar to a TV screen with no reception.
The second kind occurs less frequently but contains much brighter
light intensity and is shaped like circles or lightning bolts. Similar
to other subjects, CH11 reported seeing phosphenes with both
open and closed eyes and her phosphenes occur more frequently
in dark environments. CH11 reported that her phosphene
experiences have decreased slightly since her gene therapy
administration to the right eye, two years prior to the fMRI
study. Also similar to other subjects, CH11’s phosphene experi-
ences last a few seconds during which her vision is obscured.
fMRI results for CH11’s left and right eye (treated eye) with and
without phosphenes when presented with reversing checkerboard
stimuli are presented in Figure 5. As depicted in Figure 5, panel A,
in the absence of phosphenes, results for CH11’s left (untreated)
eye during checkerboard stimuli showed limited areas of
activations detectable only at a less stringent statistical threshold
(Uncorrected p,0.002, cca $50 mm2). In contrast, when the
right (treated) eye was stimulated in the absence of phosphenes
(panel C), CH11 presented with larger activations (Uncorrected
p,0.021, cca.25 mm2) compared to the untreated eye. When
CH11 experienced phosphenes and the stimulus was presented to
her untreated left retina, fMRI results showed significant
widespread (fdr,3%, Corrected p,0.003, cca $1000 mm2)
bilateral activations in all areas of the visual cortex extending
from medial to lateral and posterior to anterior aspects of the
occipital cortex (panel B). Similarly, the visual cortex showed
significant widespread responses (fdr,3%, Corrected p,0.004,
cca $1000 mm2) to the checkerboard stimuli presented to the
right eye (treated eye) while CH11 reported phosphenes (panel D).
C. fMRI Results of Sighted Controls
Table 4 summarizes the characteristics of significant clusters of
activations for the two sighted controls depicting the size and
Talairach coordinates for centroid location of each cluster, cluster
statistics and specific Brodmann areas of activated brain areas.
fMRI results for the left and right eye of two sighted controls using
the same reversing checkerboard stimuli are presented in Figure 6.
fMRI results for NC04’s left and right eyes (fdr,5%, Corrected
p,0.004, cca.100 mm2) are presented in panels A and C,
respectively. fMRI results for NC05’s left and right eyes (fdr,5%,
Corrected p,0.004, cca.100 mm2) are presented in panels B and
D, respectively. As depicted in Figure 6, the pattern of activation
for both NC04 and NC05 in response to the checkerboard stimuli
is more medially focused around the calcarine fissure compared to
the more widespread pattern of activations seen in the individuals
with LCA during phosphenes.
Discussion
A phenomenon characterized by the experience of seeing light
without any light actually entering the eye is called phosphenes or
photopsias. Phosphenes can occur spontaneously or via induction
by external stimuli. Previous reports regarding phosphenes have
primarily focused on externally induced phosphenes from the
occipital cortex using magnetic stimulation[14–19], alternating
[23] or direct current [11,12]. Beyond externally induced
phosphenes, phosphenes may also occur spontaneously [4–7,23–
26]. Only a hand full of these reports used fMRI to study
activations induced by these phenomenon. A more recent study
[21] used fMRI on 12 healthy subjects to test the direct
relationship between the threshold of TMS and phosphene
perceptions. Authors showed a threshold dependence for TMS
induced phosphenes and reported significantly greater distribution
of cortical activations for subjects who experienced the induced
phosphenes as opposed to those who did not [21]. In addition to
stimulated phosphenes, fMRI from spontaneous phosphene was
presented from a case report on an individual with brain infarct
[28].
In a separate self-report study Schutter and Hortensius [13]
examined a group of normal controls undergoing frontal and
occipital stimulations to compare the intensity of phosphenes
created by the retina as compared to those originated from the
occipital cortex. Based on the self-report of study participants,
phosphenes evoked by the frontal stimulations, which are
attributed to retinal origin, were significantly more intense than
those evoked by occipital stimulations [13].
Table 4. Cluster information of activated brain areas for sighted controls.
Subject ID/Eye Cluster Location (Centroid)
Cluster Size
(mm2) Centroid X Centroid Y Centroid Z t-Value p-Value
NC04/Right Left middle occipital gyrus, BA 18 5937 225 286 21 7.3937 0.0000
Left middle occipital gyrus 552 222 286 7 5.6196 0.0000
Right lingual gyrus, BA 17 24330 17 286 4 10.5394 0.0000
Left lingual gyrus, BA 18 14765 216 280 26 10.4206 0.0000
NC04/Right Left middle occipital gyrus, BA 19 795 222 287 8 4.7038 0.0000
Right middle occipital gyrus, BA 18 20466 23 285 26 8.9940 0.0000
Left cuneus, BA 18 22276 0 293 10 19.7357 0.0000
NC05/Left Left middle occipital gyrus, BA 19 966 240 268 3 5.9692 0.0000
Right inferior occipital gyrus, BA 18 850 32 284 23 4.5530 0.0000
Right middle occipital gyrus, BA 19 21298 36 264 21 19.4853 0.0000
Left lingual gyrus, BA 18 16057 24 273 21 12.0988 0.0000
NC05/Right Left cuneus, BA 18 1926 220 295 13 5.8124 0.0000
Right lingual gyrus, BA 18 13312 2 274 23 11.5988 0.0000
Right cuneus, BA 18 825 12 277 214 5.0782 0.0000
doi:10.1371/journal.pone.0086068.t004
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In retinal degenerative diseases, phosphenes may be the
manifestations of spontaneous activity in degenerating retinal
cells. In the current report we present fMRI results from 3/10
individuals with LCA2 who participated in an ongoing gene
therapy clinical trial and neuroimaging study and reported
experiencing phosphenes on a daily basis. The phosphene episodes
for the rest of LCA2 participants (7/10) occurred infrequently and
were not reported during fMRI. Functional results are presented
when the three individuals were/were not experiencing phos-
phenes to demonstrate the differences in human brain activity in
the presence or absence of these internally generated light
experiences.
As illustrated in Figures 3–5, all LCA2 subjects’ responses to the
checkerboard stimuli, showed an overwhelming amount of cortical
activations covering the entire bilateral visual cortices in the
presence of phosphenes (panels B and D). In contrast, there were
limited cortical activations recorded in the absence of phosphenes
(panels A and C). Comparison of the fMRI results for treated
(panels C) to the untreated eyes (panels A) in the absence of
phosphenes shows noticeably higher amount of significant
activations for patients’ treated eyes, similar to what we previously
reported in other subjects (e.g. CH09, CH13, NP01, CH12) who
do not regularly experience phosphenes [34,37]. The one
exception is NP02, who had received a low dose of the gene
therapy vector (see Table 1) and whose treated eye activation may
have been diminished by the macular hole, though visual function
improvements after gene therapy were reported for this subject
[32,35]. fMRI results of all three of the unilaterally injected
subjects when experiencing phosphenes clearly show that the
magnitude and distribution of cortical activations were by far more
extensive, intense and widespread throughout the visual cortices
during phosphenes. Such episodes persisted regardless of the
extent of retinal disease (including the macular hole in NP02)
[32,35], (Figure 3: Panels B and D). It is important to note that
clinical fMRI results reported on CH08 [34] in a separate study
involving unilateral administration, was carefully monitored to be
free of phosphene episodes.
The cortical activation patterns produced while subjects were
experiencing phosphenes are by far much larger and more
extensively distributed in the brain than the activation pattern
triggered by the same stimuli in normal sighted individuals. This is
illustrated in Figure 6 where fMRI results from the left and right
eyes of two normally sighted controls are presented. As expected,
both normal subjects showed significant and symmetrically
Figure 6. fMRI results for normal controls NC04 and NC05 left and right eye. (A) Left eye of NC04. (C) Right eye of NC04. (B) Left eye of
NC05. (D) Right eye of NC05. Both subjects show a more normal activation pattern associated with the checkerboard stimuli (fdr,5%, Corrected
p,0.004, cca.100 mm2). Note that the amount of activations seen in the normal control subjects is noticeably less than that of subjects
experiencing phosphene. It is also important to point out that the activation pattern for both NC04 and NC05 in response to the checkerboard stimuli
is more medially focused around the calcarine fissure than the more widespread pattern of activations seen in cases of phosphene. As shown here,
the cortical activation pattern for the LCA patients, in the absence of phosphene, is drastically different from those of normal controls where
activation is more focused in the primary visual cortex and symmetrically distributed between hemispheres for both the left and right eyes.
doi:10.1371/journal.pone.0086068.g006
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distributed bilateral activation. However, the amount and
distribution of activation in the normal control subjects are
noticeably less than what was observed in patients experiencing
phosphenes. Also, as compared to sighted controls, the pattern of
cortical activity for the LCA patients in the absence of phosphenes
is drastically lower and limited more to the extra striatal areas.
As depicted in Table 1, phosphene experiences did not appear
to be dependent on patients’ age, gender, visual acuity, RPE65
mutation type, concentration, or volume of vector they received
for gene therapy. Although the frequency and characteristics of
phosphene experiences were not queried before and after gene
therapy, some LCA2 patients reported experiencing them
‘‘somewhat’’ less frequently.
In agreement with widespread cortical activation, all three
patients reported interference with their vision while experiencing
phosphenes. In fact, all patients stated that they have to wait for
phosphene episodes to end before they can continue their
activities. Earlier studies in patients with retinitis pigmentosa by
Bittner et al [38,39] also described that patients with frequent
occurrence of photopsias or spontaneous phosphenes reported
interference with their vision. The results of fMRI presented here
(immense cortical activations) may explain the inabilities of
subjects to see while experiencing phosphenes (saturated/para-
lyzed visual cortex). The pattern of cortical activations invoked by
phosphenes along with patients’ self reports on inability to see
during phosphene episodes indicates that patients should be
queried about their phosphene experience during clinical testing,
as phosphenes could potentially interfere with results of standard
measures of visual function (visual acuity, visual field testing). Such
effects may explain the challenges of high test-to-test reproduc-
ibility in tests of Goldman visual fields in LCA2 patients described
by Roman et al. [40]. Thus, similar to the recommendation
previously set forth by Bittner et al. [38,39], our fMRI results also
strongly advocate the need for awareness of phosphene experi-
ences in all patients with retinal disease.
Although the cause of phosphenes in LCA2 patients is
unknown, we hypothesize that they are of retinal origin and due
to their RPE65-related disease. One plausible explanation
suggested by Bo´kkon [41] is that retinal phosphenes may be due
to overproduction of the ultra weak spontaneous photons [42] that
are constantly emitted from the free radical reactions of retinal
cells without any external excitation. If these biophoton emissions
exceed a certain threshold, it can appear as phosphenes to the
subject.
In summary, phosphenes may occur in a significant proportion
of LCA2 patients and the characteristics can take on several
different forms and can have an impact on the patient’s visual
experience. Although we did not perform correlations between
visual function and phosphenes, we hope data presented report
show not only that phosphenes can impact fMRI results but they
also can potentially affect other forms of visual function testing.
Future gene therapy clinical trials for retinal degeneration should
gather additional information on phosphene experiences and
correlate this information with visual function test results. fMRI
data also illustrate the potential negative impact that phosphene
perception may have on vision testing. fMRI has proven to be a
sensitive, non-invasive and reproducible test paradigm for these
purposes and can complement standard visual function testing. In
this study, fMRI confirmed the long-term effects of retinal gene
augmentation therapy in two LCA2 patients who had received
medium (CH08 & CH11) vector genome concentrations [35].
Ultimately, the incorporation of fMRI studies with standard
retinal function test paradigms will reveal whether gene therapy or
other interventions slow or halt the progression of disease and/or
improve vision. Results from the present report, however, bring
awareness to clinicians and researchers on the effect this
phenomenon may have on patients’ clinical assessment. Although
it should be noted that, as reported by Bittner et al [38],
phosphenes may be only one source of increased variability in
vision testing and other factors such as patient or operator related
variables could also lead to inconsistent test results.
Awareness of potential phosphene phenomena in patients with
retinal diseases is particularly important with respect to evaluation
of emerging therapies including gene, molecular, and cellular
therapies.
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